Valuation

Chinese lidar manufacturer paid $20 million upfront plus ongoing royalties to settle Velodyne dispute

Hesai Photonics Technology reveals monetary details of settlement, which also involves ongoing royalty payments through 2030

Chinese lidar manufacturer paid $20 million upfront plus ongoing royalties to settle Velodyne dispute
Six life sciences IP dealmaking trends to watch out for in 2021
19 Jan 2021

Six life sciences IP dealmaking trends to watch out for in 2021

Despite a turbulent 2020 for pharma transactions, it is possible to discern a few patterns for activity in the market this year

Subsidies still matter in China’s patent world, but focus is shifting overseas
14 Jan 2021

Subsidies still matter in China’s patent world, but focus is shifting overseas

USPTO report on non-market patent incentives shows how Chinese applicants are being encouraged to obtain more foreign rights

Latest

View all
22 Dec 2020

The keys to effective IP monetisation

Patent licensing is as much an art as it is a science, explain some of those featured in the new IAM Strategy 300 Global Leaders guide Read more

22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more

16 Dec 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more

12 Dec 2020

It’s time for investors to re-assess intangibles

A recent report suggests Wall Street is beginning to realise that the rise of intangible assets has thrown a spanner into time-tested valuation models Read more

News

View all
19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

7 Jul 2020

A patent's journey from IAM Market to Facebook v BlackBerry

Analysis shows that assets listed on the platform sell at a higher rate than average, while they are also litigated more often Read more

Analysis

View all
3 Dec 2020

New patent politics put US public-private partnerships under threat, says BIO’s IP chief

In an exclusive interview, Hans Sauer talks of concerns over a shift in federal strategy and argues that government research funding should not be seen as a commercial investment Read more

25 Nov 2020

Auction of Gionee’s smartphone patents a reality check for China

IP assets of bankrupt firm, once a big local handset seller, changed hands at fire-sale prices Read more

20 Nov 2020

In  Blackberry patent sale, Canada sees loss of prestige not value creation opportunity

Possible deal comes during a period of concern in the country over loss of tech crown jewels, engineering talent and the bleeding of IP assets Read more

17 Nov 2020

Data is the new frontier in healthcare IP licensing, says award-winning TTO

IAM speaks to the tech transfer office of Oregon Health & Science University about the keys to success in university-industry deal-making Read more

Insights

View all
8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more

1 Oct 2017

A round-up of IP-related quotes, observations and opinions from the recent past …

A round-up of IP-related quotes, observations and opinions from the recent past …

Read more

30 Sep 2016

McRO gives hope to US patent owners, but Section 101 uncertainty remains

After two years of uncertainty and no little gloom, a recent Federal Circuit decision may just herald the long-awaited swing-back in the pendulum that software patent owners in the United States have been waiting for. Some, though, still believe that Congress must bite the bullet and take a look at Section 101 Read more

1 Aug 2016

Brexit leaves the UPC in limbo – and that’s no bad thing

The UK vote to leave the European Union may have surprised and disappointed many in the IP community, but a rush to bypass the decision and implement the unitary patent package would be a mistake

Read more

Find an expert